Kawashima, Naomi
Akashi, Akimi
Nagata, Yasunobu
Kihara, Rika
Ishikawa, Yuichi
Asou, Norio
Ohtake, Shigeki
Miyawaki, Shuichi
Sakura, Toru
Ozawa, Yukiyasu
Usui, Noriko
Kanamori, Heiwa
Ito, Yoshikazu
Imai, Kiyotoshi
Suehiro, Youko
Kitamura, Kunio
Sakaida, Emiko
Takeshita, Akihiro
Suzushima, Hitoshi
Naoe, Tomoki
Matsumura, Itaru
Miyazaki, Yasushi
Ogawa, Seishi
Kiyoi, Hitoshi http://orcid.org/0000-0001-6382-9498
,
Funding for this research was provided by:
Scientific Research Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (17K09921)
The Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED (17ck0106251)
Article History
Received: 5 August 2018
Accepted: 31 August 2018
First Online: 24 September 2018
Compliance with ethical standards
:
: H. Kiyoi received research funding from Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc. and Celgene Corporation, consulting fees from Astellas Pharma Inc. and Daiichi Sankyo Co., Ltd., and honoraria from Bristol-Myers Squibb and Pfizer Japan Inc., N.A. received research funding from Chugai Pharmaceutical Co., Ltd. and Astellas Pharma Inc., S.M. received honoraria from Astellas Pharma Inc. and Otsuka Pharmaceutical Co., Ltd., N.U. received research funding from Nippon Shinyaku Pharmaceutical Co., Ltd., Novartis Pharma, Bristol-Myers Squibb, Celgene Corporation, Fujimoto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc. and Sysmex Co., Ltd., consulting fees from Celgene Corporation, Fujimoto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc. and Sysmex Co., Ltd., Astellas Pharma Inc., CIMIC Co., Ltd., Eli Lilly Japan, Huya Bioscience International, Janssen Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Nippon Boehiringer Ingleheim Co., Ltd., SymBio Pharmaceuticals Co., Ltd., Takeda Bio Development Center Ltd. and Zenyaku Kogyo Co., Ltd., and honoraria from Bristol-Myers Squibb, Celgene Co., Ltd., Pfizer Japan Inc., Sysmex Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. AT received research funding from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc. and Takeda Pharmaceutical Co Ltd. T.N. received research funding from FUJIFILM Corporation, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd., patents and royalties from FUJIFILM Corporation, and honoraria from Nippon Boehringer Ingelheim Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., and I.M. received honoraria from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Kyowa Hakko Kirin Co., Ltd. The other authors have no relevant conflicts to disclose.
: This study was approved by the institutional review board of each participating institution. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.